Clinical trial
A Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
NCT00606814 is registered in ClinicalTrials.gov with Infinity Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2007
- Completion date
- December 31, 2011
- Enrollment
- 60 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumors